RecruitingNot ApplicableNCT06560164

Restrictive Versus Liberal Thresholds for RBC Transfusion in ECMO

Restrictive Versus Liberal Thresholds for Red Blood Cell Transfusion in ExtraCorporeal Membrane Oxygenation - the TREC Study


Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Enrollment

526 participants

Start Date

Nov 26, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Rationale: In patients supported with extracorporeal membrane oxygenation (ECMO), transfusion of red blood cells (RBC) is very common. This is possibly due to the application of liberal thresholds and the lack of evidence-based guidelines. Although RBC transfusion can be lifesaving, it is also a risk-bearing intervention with substantial risk for morbidity and mortality in this critically ill population. Also, with increasing scarcity, RBC transfusions are becoming more expensive. Furthermore, in the past decades it has been shown in several critically ill patient populations - not on ECMO - that maintaining a restrictive hemoglobin (Hb) threshold for RBC transfusion is non-inferior, including in cardiothoracic surgery, acute myocardial infarction and septic shock. Therefore, the investigators hypothesize that a restrictive transfusion threshold for RBC is safe to apply in patients on ECMO in comparison with a liberal transfusion threshold. Objective: The primary objective of this trial is to study in a prospective randomized comparison whether a restrictive RBC transfusions strategy is non-inferior compared to a liberal strategy in patients on ECMO with respect to 90-day mortality. Study design: Prospective multi-center randomized controlled non-inferiority trial. Study population: Patients, 18 years or older, receiving ECMO. Intervention: Restrictive RBC transfusion threshold: in case the Hb transfusion trigger of 7.0 g/dL (4.3 mmol/L) is reached, 1 RBC unit at a time will be transfused. The aimed Hb target range of the restrictive/intervention group will be 7.1 - 9.0 g/dL (4.3 - 5.6 mmol/L). Liberal RBC transfusion threshold: in case the Hb transfusion trigger of 9.0 g/dL (5.6 mmol/L) is reached, 1 RBC unit at a time will be transfused. Target range of the liberal group is defined as Hb 9.1 - 11.0 g/dL Main study parameters/endpoints: The primary outcome parameter is 90-day all-cause mortality. Secondary outcomes include: 1) proportion of patients on ECMO exposed to allogeneic RBC transfusion; 2) RBC volume infused per patient during ECMO; 3) reasons for RBC transfusion other than Hb triggers; 4) transfusion reactions; 5) time on ECMO; 6) length of hospital- and ICU-stay; 7) in-ICU morbidity; 8) quality of life (QoL), iMTA Medical Consumption Questionnaire (iMCQ) and Productivity Cost Questionnaire (iPCQ) at 3, 6, 9, and 12 months; 9) costs related to a) transfusion, b) hospital admission and c) transfusion-related sequelae.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Patient is aged 18 years or older;
  • Is receiving ECMO;
  • (Deferred) informed consent.

Exclusion Criteria5

  • Not expected to survive for 24 hours when assessed;
  • Inability to receive blood products;
  • (Known) decline to blood transfusions (e.g., Jehovah's Witnesses);
  • Extracorporeal carbon dioxide removal (ECCO2R) using low blood flow devices or pumpless devices (i.e., MINILUNG ®, PrismaLung+);
  • Received ECMO over 48h before screening for eligibility.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERRed Blood Cell transfusion

When the appropriate Hb threshold is reached, patients in each group will have one unit of RBC administered at a time. Within 3 hours after the transfusion, a repeat Hb concentration will be measured. Each group will only be transfused when their Hb level falls below the transfusion threshold. In case of a outlier measurement, clinicians are advised to repeat the measurement. The RBC transfusion must take place within 4 hours when the Hb trigger was measured.


Locations(12)

Hôpital Erasme Brussels

Brussels, Brussels Capital, Belgium

KU Leuven, medical IC

Leuven, Flemish Brabant, Belgium

KU Leuven, surgical IC

Leuven, Flemish Brabant, Belgium

CHU Charleroi

Charleroi, Hainaut, Belgium

Medisch Spectrum Twente (MST)

Enschede, Drenthe, Netherlands

Maastricht Universitair Medisch Centrum+ (MUMC+)

Maastricht, Limburg, Netherlands

Amsterdam UMC, location AMC

Amsterdam, North Holland, Netherlands

Universitair Medisch Centrum Groningen (UMCG)

Groningen, Provincie Groningen, Netherlands

Leids Universitair Medisch Centrum (LUMC)

Leiden, South Holland, Netherlands

Erasmus MC

Rotterdam, South Holland, Netherlands

St. Antonius Ziekenhuis

Nieuwegein, Utrecht, Netherlands

Karolinska Universtiy Hospital

Stockholm, Stockholm County, Sweden

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06560164


Related Trials